Barry Burnette

Barry Burnette began their career in 1979 with Doctoral studies at Wright State University. In 1986, they became a Postdoctoral fellow at Washington University in St. Louis, MO, where they purified and characterized proteins in rat adipose tissue that were phosphorylated in response to insulin under Dr. John Lawrence. Barry then moved to the Laboratory of Biological Chemistry, National Cancer Institute in 1989, where they were a Postdoctoral fellow and then Senior Staff Fellow. During this time, they demonstrated that gag membrane targeting is a function of both N-terminal myristoylation and phosphorylation by PKC, and studied the role of ARF (ADP-ribosylation factor) in Golgi-mediated transport and investigated its interactions with other proteins, especially heterotrimeric G proteins. In 1993, Barry became a Scientist at Monsanto, where they conducted agricultural group regulatory studies for the FDA and EPA, and demonstrated equivalence of recombinant proteins expressed in either bacteria or genetically enhanced plants. Barry also became a Senior Principal Scientist at Pfizer Global Research and Development in 1993, where they had sixteen years of research experience in inflammation and cancer in the pharmaceutical industry, and led ESD pharmaceutical projects and supported projects through Phase 2. In 2010, Barry became a Senior Scientist at BioGenerator and an Associate Research Fellow and Senior Lab Director at Confluence Discovery Technologies and David Geffen SOM, UCLA, respectively. At Confluence Discovery Technologies, they provided cell-based assay development that was customized and validated to meet customer needs, with emphasis on the areas of Inflammation and Oncology. At David Geffen SOM, UCLA, they equipped and staffed the new Center for Integrative and Translational Imaging, and directed translational lab activities for tissue- and cell culture-based analyses to identify cancer biomarkers with prognostic and therapeutic applications for personalized health care, and high throughput screening (HTS) to identify modulators of epithelial-mesenchymal transition (EMT).

Barry Burnette obtained a Ph.D in Biomedical Sciences from Wright State University in 1987.